Clinical outcomes were assessed using Aberrant Behavior Checklist - Community (ABC-C) at baseline, week 5, and week 10, with no biological or imaging analyses performed
It was approved in 1959 as a short-term treatment for obesity, but its use has since been expanded to long-term weight management
Individual results may vary based on diagnosis, anatomy, and overall health.
UK patients should consult their GP and report any suspected adverse effects to the MHRA via the Yellow Card Scheme
Divide the total into portions that represent five to seven days of dosing each
Thus, ER36 + breast cancer cells are more tumorigenic than ER36 cells, possibly attributing to its co-segregation with CSCs